Authors
Latest:
Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLCFederico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.
Latest:
Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple MyelomaAndrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.
Latest:
Key Takeaways From DiscussionPhysicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.
Latest:
Integrating New Standards for Metastatic HER2+ Breast CancerThe first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.
Latest:
Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic AdenocarcinomaSherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.
Latest:
Dr. Baccarelli on the Effect of Environmental Factors on Cancer DiagnosesAndrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.
Latest:
Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated MelanomaDirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.
Latest:
Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRCAtrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.
Latest:
PI3K Inhibitors for PIK3CA-Mutated HR+ MBCConsiderations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.
Latest:
Our Path Forward in Leading a Revolution in Cancer CareChatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death
Latest:
Review of AENEAS Trial and Similar AgentsExperts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
Latest:
Optimizing Care of Patients With Advanced Prostate Cancer: ConclusionSummarizes the main points and benefits of multidisciplinary prostate cancer care.
Latest:
Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in PatientsJersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.
Latest:
Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast CancerEzra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.
Latest:
Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.
Latest:
Dr. Jones on Future Research Efforts in Pancreatic CancerAmy Jones, MD, discusses future research efforts in pancreatic cancer.
Latest:
Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDSGiovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.
Latest:
Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ AdenocarcinomaSamuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.
Latest:
Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLCBrian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.
Latest:
Moving From Passive to Active Clinical Trials EnrollmentThe Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.
Latest:
Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCLNausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung CancerEric Kumar Singhi, MD, discusses the identification of current care gaps and unmet needs in small cell lung cancer.
Latest:
Dr Kirtane on the Design of a Phase 1b Trial of Tbio4101 Plus Pembrolizumab in HNSCCKedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.
Latest:
USC Norris Comprehensive Cancer Center to Open Radiation Oncology and Imaging Center in Newport BeachThe new USC Norris location will feature new-to-market technology not yet available in Orange County
Latest:
Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple MyelomaShonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.
